RxDoctor Payments Data

Anantha Kamath, MD

Pain Medicine · Dallas, GANPI 1528055027

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $5,526 of the $6,805 with a category attached, or 81.2%. It is spread thinly across 37 manufacturers, the largest accounting for just 19.9% — the pattern of someone who eats at a lot of different presentations.

$6,805in general payments, 2019–2025

Across 215 payments — averaging $31.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Relievant Medsystems, Inc.$1K
  • Abbott$941
  • Boston Scientific$935
  • Medtronic$480
  • Nevro Corp.$415
  • Scilex Pharmaceuticals Inc.$306
  • plus $2K from 31 others

What the payments were for

  • Travel & lodging$99315%
  • Food & beverage$5,52681%
  • Education$2864%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,805 in reported general payments places this provider in the 75th percentile of 203 pain medicine providers in Georgia.

See all pain medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$370,133
Medicare patients
702
Services billed
3,410

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen1,094$32,137
RelistorMethylnaltrexone Bromide13$29,943
BelbucaBuprenorphine Hcl27$24,517
ZtlidoLidocaine31$22,196
MovantikNaloxegol Oxalate52$21,732
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen902$17,994
Gabapentin979$10,959
Buprenorphine35$10,007
Lidocaine51$6,952
Pregabalin375$6,625
Oxycodone Hcl401$6,483
Diclofenac Sodium103$3,919
Morphine Sulfate ErMorphine Sulfate165$3,318
Tramadol Hcl470$3,034
Lubiprostone28$2,285

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$230$29,94313 claims
Collegium Pharmaceutical, Inc.Belbuca$231$24,51727 claims
Scilex Pharmaceuticals Inc.Ztlido$306$22,19631 claims
Redhill Biopharma Inc.Movantik$12$21,73252 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 203 pain medicine providers in Georgia.

Other pain medicine in Dallas

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →